Deals

News Photos

Debiopharm Launches TrilynX - A Large-Scale Phase III Clinical Trial to Further Evaluate Xevinapant in the Treatment of Head & Neck Cancer
Click on the image below to view in Stereo 3D

Debiopharm Launches TrilynX - A Large-Scale Phase III Clinical Trial to Further Evaluate Xevinapant in the Treatment of Head & Neck Cancer
Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced today the first patient dosed in their phase III clinical trial (TrilynX) with xevinapant, an orally available antagonist of IAPs (Inhibitor of apoptosis proteins) cancer therapy in combination with CRT for LA-SCCHN patients. This prospective, randomized, double-blind, placebo-controlled, multicenter, 2-arm clinical trial is being conducted to demonstrate the superior efficacy of xevinapant vs. placebo when added to CRT in high risk head and neck patients including those affected in the throat and vocal chords (oropharynx -HPV-negative, hypopharynx and larynx). The TrilynX study is being launched worldwide in 25 countries in over 200 sites with the aim of enrolling approximately 700 patients.
More Description
Image URL

 
 
 
vlrPhone
vlrFilter
vlrMemos

Project of very low consumption, radiation and bitrate softphones
Multifunction Audio Filter with Remote Control
App to measure the quality of the voice
More Information
Free the Animation VR
AR

Play to reveal 3D images and 3D models
More Information

WhmSoft Moblog
Copyright (C) 2006-2020 WhmSoft
All Rights Reserved